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Objective: This study evaluated the effectiveness and safety of subanesthetic doses of ketamine 
using an off-label, transmucosal administration route in patients with treatment-resistant 
depression.
Methods: A retrospective chart review was conducted to identify patients who met the inclu-
sion criteria for treatment-resistant major depressive disorder. Seventeen such patients who 
received subanesthetic doses of ketamine were included. Patient demographics, efficacy (drug 
refill, clinician notes), side effects, and concurrent medications were assessed.
Results: Benefit from low-dose transmucosal ketamine was noted in 76% of subjects (average 
age 48 years, 88% female), with a dose duration lasting 7–14 days. No notable side effects 
were noted. The most common classes of concurrent medications to which ketamine was added 
were serotonin–norepinephrine reuptake inhibitors (59%), stimulants (47%), folate replacement 
(47%), and benzodiazepines (47%).
Conclusion: Our results provide preliminary evidence of the effectiveness and safety of low-
dose transmucosal ketamine in treatment-resistant patients. A controlled, prospective pilot study 
is warranted to validate these findings.
Keywords: ketamine, depression, treatment resistance, NMDA receptor, glutamate, mood disorder
Introduction
Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting 
an estimated 350 million people.1 Current limitations of pharmaceutical treatments 
include a delay in therapeutic efficacy of several weeks to months and a lack of efficacy 
in approximately a third of the patients with MDD.2,3 Revolutionizing the therapeutic 
armamentarium for the treatment of depression, the N-methyl-d-aspartate (NMDA) 
receptor antagonist ketamine administered at subanesthetic doses via an intravenous (iv) 
route can elicit robust, rapid, and sustained antidepressant effects, even in treatment-
resistant patients.4–13 However, the need for iv administration limits the use of ketamine 
to an inpatient setting, requiring support services and monitoring.14,15
To minimize the adverse events associated with iv ketamine, including acute disso-
ciative and psychotomimetic effects and cardiovascular changes,7,14–16 recent investiga-
tions have attempted alternative routes of administration to elicit rapid antidepressant 
effects.17–28 Oral administration is the simplest route to implement. However, due to 
its lower bioavailability compared to iv administration, oral ketamine often requires 
higher or more frequent dosing.17–19,24,27 Intramuscular and intranasal administration 
of ketamine have yielded more promising results with improvement in depression 
measures in patients with MDD.20,22 However, injectables are not a preferred admin-
istration route for many patients,28 and concerns surrounding inhaler use with regard 
to ease of reliable dosing and abuse potential remain.29
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A transmucosal route of administration, in which a 
small amount of liquid ketamine (approximately 1 mL) is 
absorbed through the oral mucosa rather than swallowed and 
thus increases bioavailability (17% oral vs 30% sublingual/
transbuccal),30 may prove more effective. We report herein 
a retrospective chart review of 17 patients with treatment-
resistant MDD at a psychiatric clinic in Morgantown, WV, 
USA who received low-dose ketamine using this alternative 
route of administration, which is amenable to outpatient use. 
We examined the effectiveness and tolerability of off-label use 
of ketamine when administered via the transmucosal route.
Methods
This retrospective chart review was carried out at Chestnut 
Ridge Center (Morgantown, WV, USA), a comprehensive 
psychiatric treatment facility, and comprised records of 
patients with a diagnosis of treatment-resistant MDD who 
received clinical services as part of the day hospital program 
under the care of Dr Scott Pollard, between January 2011 
and September 2013. The diagnosis of MDD was based 
on Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision (DSM-IV-TR) criteria,31 and 
treatment resistance was defined as “failure to respond to 
two or more trials of antidepressant monotherapy or failure 
to respond to four or more trials of different antidepressant 
therapies”, including augmentation, combination therapy, 
and electroconvulsive therapy.32 Trials with antidepressant 
monotherapy were each at least 6 weeks in duration. Aug-
mentation therapies included the addition of an antipsychotic 
(eg, aripiprazole), lithium, a stimulant (eg, methylphenidate), 
another class of antidepressant (eg, mirtazapine or bupropion), 
or l-methylfolate. Typically, patients who were recommended 
to the day hospital program, which is synonymous with par-
tial hospitalization, were either recently discharged from the 
inpatient unit or were failing outpatient care. Most participants 
were long-term patients with significantly persistent mental 
illness or patients who function in the community, but were 
at risk for inpatient admission or needed help through a tur-
bulent period. Services provided at the day hospital included 
medical evaluation and education by an attending psychiatrist 
and medical staff in the morning, followed by group therapy 
sessions to help increase the patients’ capacity to manage the 
symptoms of their illness and improve their quality of life. 
Of the patients with MDD who were seen in the day hospital 
setting during this period, those who were initiated on the 
transmucosal ketamine under off-label usage conditions along 
with treatment-as-usual for MDD were identified through 
the clinical notes in 18 files. Data were extracted from the 
medical charts of these 18 patients for demographic and illness 
variables, concurrent psychotropic medication use, dosing 
of ketamine, treatment response, and emergent side effects. 
Patients were classified as “responders” or “nonresponders” 
on the basis of the clinician’s notes in the medical charts and/
or drug refill history pulled from the West Virginia Board 
of Pharmacy Controlled Substance Monitoring Program 
(WVBOP CSMP) database. For the drug refill history, we 
classified a patient as a responder if he/she filled the ketamine 
prescription more than once.
The data from all of the patients in this report have been 
de-identified. None of the patients were contacted to obtain 
additional clinical or biological data for the purposes of this 
manuscript. The Institutional Review Board of West Virginia 
University (Morgantown, WV, USA) approved the study.
Results
During the study period, 18 patients who were diagnosed with 
treatment-resistant MDD received transmucosal ketamine; 
one patient was excluded from the study due to significant 
changes in medication regimen after initiation of ketamine 
treatment. The demographic, clinical, and treatment variables 
of each subject collected from the chart review are detailed 
in Table 1. The mean age of the patients was 48 years (range 
24–66), and 88% were females. Of the 17 subjects included 
in the study, three had a prior history of substance abuse, 
though none had active substance abuse disorder at the time 
ketamine was initiated. Patients were generally administered 
0.5 mg/kg to 1 mg/kg of ketamine from a 50 mg/mL vial of 
ketamine. In an effort to reduce side effects, liquid ketamine 
was placed on the tongues of the patients and they were 
instructed to hold it in their mouths for as long as possible. 
Thus, in contrast to standard oral dosing, where the drug 
is quickly swallowed, the administration route used in our 
patients may best be described as transmucosal. Moreover, 
dosing frequency started at every 14 days (based on the iv 
ketamine infusion clinical reports)4,9,10 and was reduced to 
every 10 or 7 days when it became clear that the patient had 
loss of benefit prior to the 14 days.
Out of the 17 subjects who were treated with transmucosal 
ketamine, 13 (76%) were classified as responders and four 
(24%) as nonresponders. The onset of response was gener-
ally noted within 24 hours of taking ketamine. If patients 
did not respond within 24 hours, they typically received 
no benefit from taking ketamine. Among the responders, 
the frequency of dosing was based on the duration of the 
antidepressant effect, with seven subjects dosed once every 
2 weeks, three once every 10 days, and one once every week. 
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
98
.1
42
.1
24
.1
10
 o
n 
07
-S
ep
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2669
Transmucosal ketamine as a rapid antidepressant
T
ab
le
 1
 D
em
og
ra
ph
ic
 a
nd
 t
re
at
m
en
t 
ch
ar
ac
te
ri
st
ic
s 
of
 t
he
 p
at
ie
nt
 s
am
pl
e 
on
 t
ra
ns
m
uc
os
al
 K
eT
 t
re
at
m
en
t
P
at
ie
nt
 ID
 
nu
m
be
r/
se
x/
ag
e 
(y
ea
rs
)
H
is
to
ry
 o
f 
su
bs
ta
nc
e 
ab
us
e
C
on
cu
rr
en
t 
m
ed
ic
at
io
ns
 
w
it
h 
K
E
T
D
at
e 
K
E
T
 fi
rs
t 
no
te
d 
in
 c
ha
rt
In
it
ia
l (
1s
t)
 
an
d 
m
os
t 
cu
rr
en
t 
K
E
T
 
do
si
ng
*
E
ffi
ca
cy
 in
fo
rm
at
io
n
 n
o
te
d
 
in
 c
ha
rt
Si
de
 e
ffe
ct
s
K
E
T
 R
x 
re
/fi
lle
d
 
(p
ha
rm
ac
y)
R
es
po
ns
e:
 
ye
s 
or
 
no
?
1/
F/
60
N
r
Q
ue
tia
pi
ne
a
M
ar
 2
01
3
N
a
N
a
N
o 
si
de
 e
ffe
ct
s 
no
te
d
N
on
e
N
o
c
lo
na
ze
pa
m
a
D
es
ve
nl
af
ax
in
ea
l-
m
et
hy
lfo
la
te
a
Pr
op
ra
no
lo
la
2/
F/
66
N
r
li
sd
ex
am
fe
ta
m
in
e
D
ec
 2
01
1
1s
t: 
0.
35
 m
l 
by
 m
ou
th
; 
cu
rr
en
t: 
1 
m
l 
by
 m
ou
th
, q
1w
N
a
N
o 
si
de
 e
ffe
ct
s 
no
te
d
D
ec
 2
01
1 
(0
.3
5 
m
l)
; 
M
ar
 2
01
2 
(q
1w
); 
M
ay
, 
Ju
n,
 Ju
l, 
N
ov
 2
01
2 
(1
 m
l,
 q
1w
); 
M
ar
, 
M
ay
, a
ug
 2
01
3 
(1
 m
l,
 
q1
w
)
Y
es
c
lo
na
ze
pa
m
es
ci
ta
lo
pr
am
h
al
op
er
id
ol
l-
m
et
hy
lfo
la
te
D
h
a
c
oQ
10
3/
M
/3
8
N
r
T
ra
ny
lc
yp
ro
m
in
ea
Ju
n 
20
12
1s
t: 
1 
m
g/
kg
,  
q2
w
; d
is
co
n-
tin
ue
d 
Ju
ly
 
20
12
in
ef
fe
ct
iv
e
N
o 
si
de
 e
ffe
ct
s 
no
te
d
Ju
n 
20
12
 (
q2
w
)
N
o
N
or
tr
ip
ty
lin
ea
V
en
la
fa
xi
ne
M
et
hy
lp
he
ni
da
te
l-
m
et
hy
lfo
la
te
M
ir
ta
za
pi
ne
Pr
eg
ab
al
in
4/
F/
41
N
r
li
sd
ex
am
fe
ta
m
in
e
se
p 
20
12
1s
t: 
0.
5 
m
g/
kg
,  
q2
w
; d
is
co
n-
tin
ue
d 
Ju
ly
 
20
13
N
a
N
o 
si
de
 e
ffe
ct
s 
no
te
d
se
p 
20
12
 (
0.
5 
m
g/
kg
, q
2w
); 
D
ec
 2
01
2 
(0
.5
 m
g/
kg
, q
10
d)
Y
es
Pr
op
ra
no
lo
l
a
ri
pi
pr
az
ol
e
c
ita
lo
pr
am
h
yd
ro
xy
zi
ne
li
th
iu
m
D
ox
az
os
in
5/
F/
44
N
r
D
ox
az
os
in
a
ug
 2
01
2
c
ur
re
nt
: 
0.
5 
m
g/
kg
, 
q1
0d
Pa
tie
nt
 r
ep
or
te
d 
do
in
g 
be
tt
er
 o
n 
O
ct
 2
01
2
N
o 
si
de
 e
ffe
ct
s 
no
te
d
a
ug
 2
01
2 
(0
.5
 m
g/
kg
, q
2w
); 
Ju
l 
20
13
 (0
.5
 m
g/
kg
, q
2w
)
Y
es
h
yd
ro
xy
zi
ne
D
es
ve
nl
af
ax
in
e
l-
m
et
hy
lfo
la
te
Fi
sh
 o
il
6/
F/
24
N
r
V
en
la
fa
xi
ne
se
p 
20
12
1s
t: 
0.
5 
m
g/
kg
, 
q2
w
Pa
tie
nt
 d
is
ch
ar
ge
d 
fr
om
 d
ay
 
ho
sp
ita
l J
ul
 2
01
3
N
o 
si
de
 e
ffe
ct
s 
no
te
d
se
p 
20
12
  
(0
.6
7 
m
l,
 q
2w
)
N
o
D
es
ve
nl
af
ax
in
e
c
lo
na
ze
pa
m
Pr
op
ra
no
lo
l
7/
F/
51
N
r
la
m
ot
ri
gi
ne
Ju
l 2
01
2
c
ur
re
nt
:  
0.
5 
m
g/
kg
, 
q1
0d
Pa
tie
nt
 r
ep
or
te
d 
m
oo
d 
is
 g
oo
d 
si
nc
e 
ta
ki
ng
 k
et
am
in
e
N
o 
si
de
 e
ffe
ct
s 
no
te
d
Ju
l 2
01
2;
 Ju
n 
20
13
 
(0
.5
 m
g/
kg
, q
2w
)
Y
es
h
yd
ro
xy
zi
ne
Fl
uo
xe
tin
e
N
-a
ce
ty
lc
ys
te
in
e
(C
on
tin
ue
d)
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
98
.1
42
.1
24
.1
10
 o
n 
07
-S
ep
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2670
Nguyen et al
T
ab
le
 1
 (
Co
nt
in
ue
d)
P
at
ie
nt
 ID
 
nu
m
be
r/
se
x/
ag
e 
(y
ea
rs
)
H
is
to
ry
 o
f 
su
bs
ta
nc
e 
ab
us
e
C
on
cu
rr
en
t 
m
ed
ic
at
io
ns
 
w
it
h 
K
E
T
D
at
e 
K
E
T
 fi
rs
t 
no
te
d 
in
 c
ha
rt
In
it
ia
l a
nd
 
m
os
t 
cu
rr
en
t 
K
E
T
 d
os
in
g
E
ffi
ca
cy
 in
fo
rm
at
io
n
 n
o
te
d
 
in
 c
ha
rt
Si
de
 e
ffe
ct
s
K
E
T
 R
x 
re
/fi
lle
d
 
(p
ha
rm
ac
y)
R
es
po
ns
e:
 
ye
s 
or
 
no
?
8/
F/
28
N
r
D
ul
ox
et
in
e
Fe
b 
20
12
D
is
co
nt
in
ue
d 
Ju
ly
 2
01
3
N
ot
e 
th
at
 k
et
am
in
e 
co
nt
in
ue
d 
to
 w
or
k 
w
el
l, 
w
ith
 s
tr
on
g 
ef
fe
ct
s 
th
e 
fo
llo
w
in
g 
da
y 
in
 Ju
l 2
01
2;
 s
til
l 
be
ne
fit
tin
g 
Se
p 
20
12
N
o 
si
de
 e
ffe
ct
s 
no
te
d
N
on
e
Y
es
Pr
eg
ab
al
in
lo
ra
ze
pa
m
D
ox
az
os
in
9/
F/
47
N
r
li
sd
ex
am
fe
ta
m
in
e
O
ct
 2
01
2
1s
t: 
0.
5 
m
g/
kg
, 
q2
w
; c
ur
re
nt
: 
0.
5 
m
g/
kg
, q
2w
Pa
tie
nt
 s
til
l o
n 
ke
ta
m
in
e 
as
 o
f 
O
ct
 2
01
3
N
o 
si
de
 e
ffe
ct
s 
no
te
d
O
ct
 2
01
2 
(0
.5
 m
g/
kg
, q
2w
); 
Ju
n 
20
13
 
(0
.5
 m
g/
kg
, q
2w
)
Y
es
Fl
uo
xe
tin
e
l-
m
et
hy
lfo
la
te
10
/F
/5
1
N
r
V
en
la
fa
xi
ne
Ju
l 2
01
2
1s
t: 
1 
m
g/
kg
, 
q2
w
; c
ur
re
nt
: 
0.
5 
m
g/
kg
, q
2w
Pa
tie
nt
 r
ep
or
te
d 
m
ig
ra
in
es
 a
nd
 
m
oo
d 
ar
e 
be
tt
er
 o
n 
a
ug
 2
01
2
li
gh
t 
he
ad
ac
he
s
Ju
l 2
01
2 
(a
s 
di
re
ct
ed
)
Y
es
lo
ra
ze
pa
m
11
/F
/4
2
N
r
li
sd
ex
am
fe
ta
m
in
e
a
ug
 2
01
2
1s
t: 
0.
5 
m
g/
kg
, 
q2
w
N
ot
e 
th
at
 t
he
re
 is
 c
on
tin
ue
d 
im
pr
ov
em
en
t 
on
 O
ct
 2
01
2
N
o 
si
de
 e
ffe
ct
s 
no
te
d
a
ug
 2
01
2,
 F
eb
 2
01
3,
 
Ju
n 
20
13
 (
0.
5 
m
g/
kg
, 
q2
w
)
Y
es
a
m
ph
et
am
in
e/
de
xt
ro
am
ph
et
am
in
e
D
ul
ox
et
in
e
D
ox
ep
in
l-
m
et
hy
lfo
la
te
12
/F
/5
7
N
r
a
m
ph
et
am
in
e/
de
xt
ro
am
ph
et
am
in
ea
Ja
n 
20
12
N
a
N
ot
e:
 p
at
ie
nt
 is
 d
oi
ng
 w
el
l o
n 
ke
ta
m
in
e 
on
 Ja
n 
20
13
N
o 
si
de
 e
ffe
ct
s 
no
te
d
Ja
n 
20
12
, a
ug
 2
01
2,
 
Ja
n 
20
13
 (
q2
w
)
Y
es
T
ra
zo
do
ne
a
D
ox
ep
in
a
Bu
pr
op
io
na
13
/F
/5
6
a
lc
oh
ol
 
an
d 
ot
he
r 
su
bs
ta
nc
es
V
ila
zo
do
ne
Fe
b 
20
13
1s
t: 
0.
5 
m
g/
kg
, 
q2
w
; c
ur
re
nt
: 
0.
5 
m
g/
kg
, q
2w
N
ot
e:
 p
at
ie
nt
 is
 d
oi
ng
 w
el
l a
nd
 
m
oo
d 
im
pr
ov
ed
 t
he
 n
ex
t 
da
y 
af
te
r 
ke
ta
m
in
e 
tr
ea
tm
en
t
N
o 
ad
ve
rs
e 
ef
fe
ct
s 
(s
pe
ci
fie
d 
in
 c
ha
rt
)
Fe
b,
 Ju
l 2
01
3 
(0
.5
 m
g/
kg
, q
2w
)
Y
es
T
ra
zo
do
ne
a
ri
pi
pr
az
ol
e
g
ab
ap
en
tin
Bu
sp
ir
on
e
l-
m
et
hy
lfo
la
te
D
ul
ox
et
in
e
14
/M
/6
5
a
lc
oh
ol
Pr
op
ra
no
lo
l
D
ec
 2
01
2
N
a
R
x 
fil
le
d,
 b
ut
 u
nc
le
ar
 if
 h
e 
to
ok
 it
 
be
ca
us
e 
of
 o
th
er
 h
ea
lth
 is
su
es
 (i
n 
an
d 
ou
t o
f t
he
 h
os
pi
ta
l a
 lo
t w
ith
in
 a
 
sh
or
t t
im
e 
sp
an
); 
Pa
tie
nt
 u
nd
er
w
en
t 
10
 e
c
T 
tr
ea
tm
en
ts
 s
ta
rt
in
g 
in
 
Ja
n 
20
13
 (i
m
pr
ov
ed
 a
fte
r 
6 
ec
T
 
tr
ea
tm
en
ts
; b
ut
 d
isc
on
tin
ue
d 
af
te
r 
10
 
tr
ea
tm
en
ts
 d
ue
 to
 a
dv
er
se
 m
em
or
y 
ef
fe
ct
s)
 a
nd
 w
as
 in
te
re
st
ed
 in
 ta
ki
ng
 
ke
ta
m
in
e 
as
 a
n 
an
tid
ep
re
ss
an
t a
nd
 
w
illi
ng
 to
 r
es
ta
rt
 e
c
T 
on
 M
ar
 2
01
3
D
ec
 2
01
2 
(a
s 
di
re
ct
ed
)
N
o
O
m
eg
a-
3 
fa
tt
y 
ac
id
s
l-
m
et
hy
lfo
la
te
N
-a
ce
ty
lc
ys
te
in
e
h
yd
ro
xy
zi
ne
r
is
pe
ri
do
ne
c
lo
na
ze
pa
m
se
rt
ra
lin
e
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
98
.1
42
.1
24
.1
10
 o
n 
07
-S
ep
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2671
Transmucosal ketamine as a rapid antidepressant
The remaining two responders (#8 and #18) did not have 
adequate information on maintenance dosing regimens. Of 
the 13 responders, two (#2 and #4) were based solely on the 
drug refill history (ie, the prescription was filled more than 
once but their charts had no note of efficacy). In addition, the 
clinical notes for two patients (#8 and #12) explicitly stated 
continued benefits with ketamine 6 months or more after the 
first ketamine treatment.
Of the four nonresponders (50% females), two had 
their prescriptions filled once: one had a note of inefficacy 
in the patient chart, and the other subsequently underwent 
and responded to ten electroconvulsive therapy treatments 
approximately 1 month after the prescription was filled. The 
other two nonresponders had no ketamine refill history and 
no reports of efficacy in their charts.
Other medications taken concurrently with ketamine 
included serotonin–norepinephrine reuptake inhibitors 
(n=10), stimulants (n=8), folate replacement (n=8), benzodi-
azepines (n=8), selective serotonin reuptake inhibitors (n=6), 
antipsychotics (n=6), and others (Table 2). Potential drug 
interactions or adverse effects are summarized in Table 3. 
Overall, no serious adverse events were noted in any of the 
subjects initiated on transmucosal ketamine. The two mild 
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Table 2 concurrent medications with ketamine
Medication Subjects taking 
the drug (%)
sNri 59%
stimulant 47%
Folate replacement 47%
Benzodiazepine 47%
ssri 35%
antipsychotic 35%
h1-antihistamine 29%
Beta blocker 24%
alpha blocker 24%
Tca 18%
Neuropathic pain treatment (pregabalin) 12%
Abbreviations: sNri, serotonin–norepinephrine reuptake inhibitor; ssri, selective 
serotonin reuptake inhibitor; Tca, tricyclic antidepressant.
Table 3 Potential drug interactions/adverse effects with 
ketamine
Medications Side effects
clonazepam, lorazepam, pregabalin, nortriptyline, 
hydroxyzine, doxepin, trazodone
cNs depression
haloperidol, mirtazapine, tranylcypromine additive cNs effects
Propranolol, doxazosin hypotension
lisdexamfetamine, amphetamine/
dextroamphetamine
cardiac effects
Abbreviation: cNs, central nervous system.
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side effects reported were transient light headache (n=1) and 
slight dizziness (n=1).
Discussion
This is an exploratory study in a naturalistic setting of the 
potential effectiveness and tolerability of transmucosal 
ketamine in 17 patients with treatment-resistant MDD. 
The findings in this chart review support previous reports 
of effectiveness of low-dose ketamine in rapidly alleviat-
ing symptoms of MDD, with effects lasting up to 2 weeks. 
Importantly, in contrast to iv ketamine, the administration of 
ketamine using the transmucosal route is better tolerated and 
has minimal psychiatric side effects. All patients were in a 
partial hospitalization program, wherein they were seen fre-
quently and had adequate nursing support for administration/
education and observation with respect to ketamine. There 
were no adverse effects that would cause clinical concern for 
attempting to address depressive symptoms quickly in an at-
risk, treatment-resistant population who otherwise are often 
being referred to high levels of care such as acute inpatient 
hospitalization.
A similar exploratory study has been conducted using 
low-dose sublingual ketamine in refractory unipolar and 
bipolar depression, in which patients were instructed to 
hold approximately 1 mL liquid ketamine in their mouths 
for 5 minutes and then swallow it.23 In that report, ketamine 
also produced rapid and relatively sustained antidepressant 
effects with only mild and transient light-headedness as a 
common side effect (no euphoria, psychotic or dissociative 
symptoms).23 Moreover, like the exploratory study using 
sublingual ketamine, the nature of our study provided an 
opportunity for reviewing treatment response in a “dirty” 
population that may be more representative of the treatment-
resistant psychiatric patient pool, which is not possible with 
randomized controlled trials. Oftentimes, as in our chart 
review, the patients have multiple medical and psychiatric 
comorbidities, including but not limited to prior substance 
use disorders, chronic pain, attention deficit hyperactivity 
disorder, borderline personality disorder, and anxiety disor-
ders like posttraumatic stress disorder. With that in mind, it 
is reassuring that the addition of low-dose ketamine had no 
serious adverse effects, including no drug–drug interactions 
or recurrence of substance misuse/abuse. Moreover, though 
side effects were not systematically monitored, it is important 
to note that these patients were a part of the day hospital 
program at the psychiatric center, participating in group 
therapy sessions often within 1 hour of taking transmucosal 
ketamine and having adequate medical support during their 
stay. None of the patients in our study discontinued using 
ketamine because of adverse events, with only mild, transient 
side effects noted (headache, dizziness).
This study has many limitations which are inherent to 
using a retrospective design. These include the lack of ran-
domization and consistent baseline clinical data. Moreover, 
data for each variable were not available in every chart. As 
this was not a controlled study and our patient population 
had taken a number of medications which may affect the 
antidepressant effects and pharmacokinetics of ketamine, we 
were also unable to determine whether the positive effects 
of treatment were due to ketamine alone or a combination of 
ketamine and other therapies. In addition, no standardized 
clinical measures were used to evaluate depressive symptoms 
and adverse effects, including the monitoring of vital signs. 
Tachycardia and increased blood pressure in particular have 
been commonly observed following low-dose ketamine 
injections14 and should be systematically examined in future 
studies with transmucosal ketamine. The reliance on the drug 
refill history of a patient as an indicator of therapeutic efficacy 
introduces additional concerns that go beyond uncertainties 
regarding patient compliance and medication adherence. With 
the drug refill history omitted, however, ten of the 17 patients 
(ie, 59%) would have been classified as “responders” from 
clinical notes of efficacy in the charts, which remains a 
sizeable proportion of the treatment-refractory population. 
Nevertheless, due to these limitations, a prospective, pilot 
study is strongly warranted to validate the efficacy of the 
transmucosal route of ketamine as a viable option for eliciting 
fast-acting and sustained antidepressant effects, with a side 
effect profile suitable for use in outpatients. Whether ketamine 
remains as effective if patients were withdrawn from their 
routine antidepressants is also of great interest.
Conclusion
This retrospective chart review describes the use of trans-
mucosal ketamine for treatment-resistant depression and 
suggests that it may be a safe, tolerable, and effective anti-
depressant in some depressed patients.
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